Dr. Nigel Stevenson from Exubrion Therapeutics® and Vivos Inc CEO Dr. Mike Korenko have just submitted a joint abstract entitled “Precision Radionuclide Therapy for Treating Veterinary Cancerous Tumors and Osteoarthritis” to the 11th International Conference on Isotopes on July 23-24 in Saskatoon, SK Canada.
Nigel is Exubrion Therapeutics’ Chief Operations Officer and is also the Vivos Inc Chief Science Advisor. The two companies cooperate since they are in totally different therapy markets. The CEOs of both companies decided that it is in their best interest to promote the benefits of precision radionuclide therapy.
Home Page Cover Image:
Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.
Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.
RadioGel™ is a hydrogel liquid containing tiny yttrium-90 (90Y) phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
IsoPet® Therapy Application(s)
Precision Radionuclide Therapy (PRnT)
Vivos Inc. - (OTCQB: RDGL) Investor Relations
Contact
| bg-primary | |
| bg-primary-light | |
| bg-primary-dark | |
| bg-secondary | |
| bg-secondary-dark |
| body | |
| top-header | |
| header | |
| content |
| background | |
| text color | |
| link color | |
| horizontal line |
| style 1 | |
| style 2 | |
| style 3 |
| social icons | |
| navigation color | |
| subnav background |
| background color | |
| navigation color |
Note: All changes made here will be applied to your entire website.
Write a comment